Physician profile
Eshan Patel
NPI 1770821498
$420,204.62
in general payments reported to CMS, 2019-2025
33 companies · $231K in 2025
The $231K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $2,265 · 2021: $21K · 2022: $42K · 2023: $74K · 2024: $50K · 2025: $231K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $72K · Travel and Lodging: $44K · Consulting Fee: $29K · Food and Beverage: $11K · Education: $39.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,610.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $71,662.50 |
| Travel and Lodging | $44,056.98 |
| Consulting Fee | $29,087.50 |
| Food and Beverage | $10,693.12 |
| Education | $39.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $176,788.17 | 2020-2025 | Carvykti, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $117,416.86 | 2019-2025 | Calquence, Tagrisso, Datroway |
| Novocure INC. | $111,394.77 | 2023-2025 | Optune Lua (Novottf-200t), Optune Gio, Optune |
| Pfizer INC. | $4,646.60 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $3,247.50 | 2022-2024 | Darzalex |
| Astellas Pharma US INC | $3,231.11 | 2019-2025 | Vyloy |
| Exelixis INC. | $1,470.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $256.47 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $239.46 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $185.31 | 2020-2025 | Opdualag, Eliquis |
| Daiichi Sankyo INC. | $169.56 | 2021-2025 | Enhertu |
| Gilead Sciences, INC. | $156.46 | 2022-2025 | Trodelvy |
| Seagen INC. | $120.33 | 2021-2023 | |
| Celgene Corporation | $105.91 | 2021-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $103.57 | 2020-2024 | Keytruda, Welireg |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $103.30 | 2020-2023 | Verzenio, Jaypirca |
| Myriad Genetic Laboratories, INC. | $62.52 | 2021-2022 | |
| Epizyme, INC. | $59.24 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.06 | 2019-2025 | |
| Incyte Corporation | $53.31 | 2019-2021 | |
| Array Biopharma INC | $42.42 | 2021-2022 | |
| Eisai INC. | $41.78 | 2022 | |
| Amgen INC. | $38.12 | 2022 | |
| Genzyme Corporation | $29.61 | 2022 | |
| Beigene USA, INC. | $29.44 | 2021-2022 | |
| Myovant Sciences INC. | $29.25 | 2021 | |
| G1 Therapeutics, INC. | $24.40 | 2023 | Cosela |
| Dova Pharmaceuticals | $21.05 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.05 | 2019 | |
| Kite Pharma, INC. | $18.28 | 2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Abbvie INC. | $14.89 | 2022 | |
| Tg Therapeutics, INC. | $14.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eshan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.